Pro-Pharmaceuticals reports "promising" data

October 11, 2007 08:01 AM E-mail| |Comments ()| Text size +

Pro-Pharmaceuticals Inc. of Newton reported "promising early data" from a Phase II trial of a colorectal cancer treatment.

The trial is for a first-line treatment of patients with metastatic, unresectable colorectal cancer who are unable to tolerate intensive chemotherapy, the company said.

Pro-Pharmaceuticals reported that three of seven evaluable patients in the test have experienced tumor shrinkage of greater than 30 percent; in addition, none of the patients in the test experienced severe side effects.
(By Chris Reidy, Globe staff)

Email this article

Invalid email address
Invalid email address

Sending your article

Your article has been sent.

Col3